MimoPools™

The latest innovation from the experts in PepSets™ Peptide Library synthesis, MimoPools are uniquely suited to cutting-edge research applications.


These modern peptide libraries are aliquoted and pooled into one convenient peptide mix for maximum manouvereability.

Expanded Applications

MimoPools™ takes standard peptide library screening studiesfurther with critical applications in antigen-specific T-cell response studies, epitope mapping, and immune monitoring.


Pivotal in the continuing worldwide SARS-CoV-2 research, strategically synthesised peptide pools can contain specific sequences for mutations in key proteins or complete protein sequences for each variant.

High Quality Peptides

MimoPools™ are produced using the same validated peptide library synthesis procedureswe’re known for. Our stringentquality control measures guarantee identity and purity, and all peptide pools are supplied with a Certificate of Analysis and Mass Spectrometry data. 


Designed For Success

MimoPools™ are expertly designed on a case-by-case basis to include pre-synthesised catalogue peptides or made-to-order sequences, with all of the modification and customisation option typical of a standard peptide library.


The design of truncated peptide pool has been optimised for T-cell studies by the inclusion of four strategically truncated lengths of the same sequence in each pool.

MimoPools™ are available as-synthesised or purified up to 95%. These peptide pools are supplied as freeze-dried aliquots, offering long-term stability, and allowing MimoPools™ to be used and reused at your convenience.

Contact us today for a quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

✉ useast@mimotopes.com

✉ uswest@mimotopes.com



asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Cutting the carbon footprint of pharma’s supply chainGo to article: In this issueGo to article: ContentsGo to article: CSafe GlobalGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: HOF SonderanlagenbauGo to article: CommentGo to article: Is price control by stealth the future for the United States?Go to article: FDA approves Janus kinase inhibitors Rinvoq and Cibinqo despite safety concernsGo to article: Psychedelics: the next trip for CMOsGo to article: Over $1bn raised in venture capital funding for gene editing in 2021Go to article: SkyepharmaGo to article: In DepthGo to article: How AI could unlock the medical potential of psychedelicsGo to article: Covid-19 vaccine mixing: could heterologous boosters improve immunity?Go to article: Uneven supply patterns hinder US rollout of Covid-19 antiviralsGo to article: Cutting the carbon footprint of pharma’s supply chainGo to article: Molnupiravir supplies dominate in times of Paxlovid scarcityGo to article:  Wek-tec Go to article: In DataGo to article: Revealed: pharma leaders in precision, personalised medicineGo to article: Asia-Pacific is seeing a hiring boom in pharmaceutical cybersecurity rolesGo to article: Venture financing deals in pharma rise in H2 2021Go to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: Controlant Company InsightGo to article: ControlantGo to article: Event: Clinical Trial Supply New England 2022Go to article: EventsGo to article: Next issue